(1) Clients who have been in treatment because of opioid problem use (4200), cocaine or amphetamine problem use (200), including an estimate of the number of treated persons for hallucinogens, sedatives or cannabis (400).

(2) The information refers to all clients treated in 2009 for problems with illegal substances in outpatient healthcare facilities (2010 National Report; table 5-3: Number of clinics and number of addictive substance users treated in 2000-2009 (Nechanská et al. 2010; Institute of Health Information and Statistics, 2010a). This figure is an under-estimate as it only refers to clients being treated within these types of facilities and not all available treatment providers in the Czech Republic.

(3) No control for double-counting beyond centre level, estimates based on selected types of specialised treatment centres and extrapolated based on coverage estimates. Outpatient calculation based on 54.385 clients (no individual data, based on 'last episode in a given year in a given centre' related to opiate-related disorders (F11.x), all treatments); inpatient calculation based on clients having ended a treatment episode in a given year (probability to have more than one inpatient episode per year is very low). Additional information: 31.496 hospital treatments due to F11 (in 2009), unclear overlap with specialised treatment centres (estimates based on data from specialised outpatient treatment: 12.6-16.2% parallel treatment in/ discharge to hospitals). Additional source of information based on national substitution register: 77.400 registered clients in substitution treatment (data from specialised treatment centres: For 34.6% of clients treated in outpatient centres and 3.2% of inpatient clients a paral

(4) In addition of clients in opioid substitution treatment, this number consist of 46 clients in Wismari hospital in detoxification treatment and 100 clients in the Tallinn Children's Hospital in detoxification treatment.

(5) The information refers to all clients treated in 2010. Each case (episode) sought treatment for problem (illicit)drug use (excluding those who reported alcohol, hypnotic or sedatives as their main problem drug). The cases include those who reported one of the following as their main problem drug: an opiate, cocaine, a stimulant, hallucinogens, volatile inhalants and cannabis.

(6) The above data come from 86 officially recognized centres which offered treatment services in 2011 and delivered relevant data. They consist of 39 drug-free treatment programmes (2,264 clients), 39 substitution treatment units (6,783 clients), 7 drug-free treatment programmes in prison (394 clients) and 1 outpatient detoxification programme (280 clients). The data collection is based on the 'Treatment Questionnaire' (2010), which is a revised version of the 'Treatment Unit Form/TUF A'. The collected information is controlled annually to check internal consistency. The figure does not include readmissions within the year in the same unit; whereas clearance for double entries among different units is not feasible.

(7) The data refers to clients in treatment for problem heroin use, problem cocaine use, problem amphetamine use, and problem cannabis use. Source: Government Delegation for the National Plan on Drugs.

(8) Number of clients with a prescription of opioid substitution treatment + number illicit drug users seen in specialised centres (CSAPA) but not in opioid substitution treatment. Missing cases : illicit drug users treated in hospitals (outside specialised centres located within hospitals).

(9) Data refers to clients of the public drug outpatient treatment services (Ser.T.) in the year 2010.The total number of individual clients refers to clients who received treatment by Ser.T. for their drug problem. The clients can be treated in Ser.T. (outpatient service), in therapeutic communities (inpatient service) or in prison. The total number of treatment episodes refers to pharmacologically and/or psychosocial treatment performed by Ser.T. for clients who have drug problems. The clients can be treated in Ser.T. (outpatient service), in therapeutic communities (inpatient service) or in prison.

(10) The total number of persons in treatment in 2011 is controlled for double counts (clients entering treatment in the reporting year and those in treatment during the reporting year who had continued treatment from the previous year/s).

(11) Data refers to opiates, amphetamines and cocaine users in treatment in 2009.

'(12) The estimate of the total number of clients in treatment is based on the following considerations and refers to problem opioid users in treatment. a) All outpatient clients in DOKLI with primary drug opiates (treatment prevalence) in 2011: 4216 b) All inpatient clients in DOKLI with primary drug opiates (treatment prevalence) in 2011: 1231c) Coverage of DOKLI outpatient: 93% d) Coverage of DOKLI inpatient: 85% e) Estimate for double counting in DOKLI based on data for Vienna: 21,7% f) Total clients in substitution treatment database in 2011: 16782 g) Estimation for overlap of DOKLI and substitution treatment database based on the DOKLI question 'do you already receive substitution treatment' for clients with primary drug opiates: outpatient: 56,7% inpatient 54,3% Problems and limitations: c + d) the coverage is roughly estimated based on the percentage of treatment facilities delivering data to DOKLI e) the estimate is based on data from Vienna - maybe it is an overestimation for rural areas f) This

(13) Data come from the reporting system conducted by Institute of Psychiatry and Neurology covering only residential treatment due to mental and behavioural disorders caused by using illicit drugs. The residential system of statistical reporting is based on individual statistical questionnaires. Each questionnaire is coded. It is possible to eliminate double counting of persons who enter treatment several times a year, sometimes in many facilities.

(14) Individuals within at least one treatment episode during the reporting year. Includes: Opiates, Cocaine, stimulants, hypnotics and sedatives, hallucinogens, volatile and cannabis.

(15) Data sources: treatment centres under coordination of Ministry of Health, NAA, private centres and prisons. However not all centres (which are under coordination of Ministry of Health) have reported.

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>